Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results -More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July- -Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70 respectively, across multiple indications- -Clinical trials opened for CTX112 in systemic lupus erythematosus (SLE) a ...

Another stock from the Zacks Medical - Biomedical and Genetics industry, Alnylam Pharmaceuticals (ALNY) , is soon expected to post loss of $0.71 per share for the quarter ended June 2024. This estimate indicates a yearover-year change of +67.9%. Revenues for the quarter are expected to be $452.73 million, up 42% from the year-ago quarter. The market expects CRISPR Therapeutics AG (CRSP) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. ...

The company's shares have seen a decrease of 2.93% over the last month, not keeping up with the Medical sector's gain of 0.37% and the S&P 500's gain of 1.96%. CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$5.51 per share and revenue of $89.43 million. These results would represent year-over-year changes of -184.02% and -75.91%, respectively. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have d ...

We expect CRISPR Therapeutics (CRSP) to surpass expectations when it reports second-quarter 2024 results next month. The Zacks Consensus Estimate for CRSP's total revenues currently stands at $8.39 million. CRISPR Therapeutics has a positive earnings surprise history. The company beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 117.78%. In the last reported quarter, CRSP's earnings beat estimates by 12.27%. Other Stocks to Consider Amgen Inc. (AMGN) has an Ear ...

California's giant redwood trees were once tiny sprouts or seeds. Likewise, the world's biggest companies were once much smaller. Trees and companies can grow significantly over time -- at least some of them. Prosper Junior Bakiny (CRISPR Therapeutics): It's always an important milestone for a clinical-stage biotech to launch its first product. That's what happened with CRISPR Therapeutics last year. The gene-editing specialist earned approval for Casgevy, developed in collaboration with Vertex Pharmaceutic ...

Other purposes of gene editing include making crops more resistant to viruses and bacteria and better able to cope with extremes of heat and cold caused by global warming. One day, gene editing could alter people's DNA and prevent certain diseases from developing. In some circles, gene editing is controversial, though the science behind it is widely viewed as legitimate. Source: rafapress / Shutterstock.com Vertex Pharmaceuticals (VRTX) Vertex Pharmaceuticals is a more mature and established biotech company ...

CRISPR Therapeutics AG (CRSP) shares ended the last trading session 9.2% higher at $62.75. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 7% loss over the past four weeks. This rise in share price is attributable to positive investor expectations for the company's sole-marketed product Casgevy which received marketing approval in late 2023/early 2024. Marketed in partnership with Vertex Pharmaceuticals, Casgevy is ...

That said, it's not a good idea to rely on six months' worth of data to decide which stocks to buy. These two biotechs will likely reverse positions over the long run, with CRISPR performing much better than Ocugen. Read on to find out why the former is worth investing in while the latter should be avoided. Now, it's too early to look at CRISPR Therapeutics' financial results. Casgevy hasn't been on the market very long, not to mention that administering this therapy takes a while. The biotech's revenue in ...

The company's stock has dropped by 11.68% in the past month, falling short of the Medical sector's loss of 1.82% and the S&P 500's gain of 4.44%. For the full year, the Zacks Consensus Estimates project earnings of -$5.51 per share and a revenue of $89.43 million, demonstrating changes of -184.02% and -75.91%, respectively, from the preceding year. Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a pro ...

But the silver lining of that process is you have time to accumulate a position. And, by not going all in, there's time to evaluate your thesis for owning the stock as time goes by. Here are three biotech stocks to buy while they're still in their early stages of growth. Recently, CRISP received Food and Drug Administration (FDA) approval for CASGEVY, its lead candidate for treatment of sickle cell disease and beta-thalassemia. This treatment is now available in 25 authorized centers around the world. Cassa ...